LB Pharmaceuticals Inc (LBRX)
| Market Cap | 346.52M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -29.43M |
| Shares Out | 22.44M |
| EPS (ttm) | -116.88 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 176,260 |
| Open | 15.96 |
| Previous Close | 16.07 |
| Day's Range | 15.06 - 16.34 |
| 52-Week Range | 13.36 - 20.25 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 46.33 (+200.07%) |
| Earnings Date | Nov 10, 2025 |
About LBRX
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 1 clinical trial for the treatment of bipolar I depression; and in pr clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York. [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for LBRX stock is "Strong Buy." The 12-month stock price target is $46.33, which is an increase of 200.07% from the latest price.
News
LB Pharmaceuticals Appoints James Rawls, Pharm.D., as Senior Vice President of Regulatory Affairs
NEW YORK, Oct. 14, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced the appointment of James Rawls, Pharm.D., as Senior Vice Presi...
LB Pharmaceuticals to Present Three Posters at 38th ECNP Congress Highlighting Clinical Activity and Safety Profile of LB-102 in Schizophrenia, Including Positive Effects on Cognition and Negative Symptoms
NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced that three posters featuring new and previously reported analy...
LB Pharmaceuticals Strengthens Board of Directors with Appointments of William Kane and Rekha Hemrajani
NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced the appointments of William Kane and Rekha Hemrajani to its B...
LB Pharma valued at $382 million as shares jump in New York debut
LB Pharmaceuticals' shares rose 27% in their Nasdaq debut on Thursday, giving the biotech firm a valuation of $381.9 million and opening the door for companies looking to tap the public markets before...
LB Pharmaceuticals raises $285 million in US IPO
LB Pharmaceuticals raised $285 million in its U.S. initial public offering, the biotech firm said on Wednesday, marking the first sizable biotech IPO since February.
LB Pharmaceuticals Announces Pricing of its Upsized Initial Public Offering
NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals”) today announced the pricing of its upsized initial public offering of 19,000,000 shares of its common stock a...
LB Pharmaceuticals eyes $322 million valuation in biotech IPO amid sector drought
Cash-strapped drug developer LB Pharmaceuticals said on Monday it was aiming for a valuation of up to $321.6 million in its New York initial public offering, potentially setting up the first sizable U...
LB Pharmaceuticals Launches $100 Million IPO Effort
LB Pharmaceuticals Inc. is preparing a $100 million IPO to fund Phase 3 trials for its schizophrenia drug, LB-102, after positive Phase 2 results. The company targets a large, growing schizophrenia dr...
Neuropsychiatry biotech LB Pharmaceuticals files for a $100 million IPO
LB Pharmaceuticals, a Phase 3 biotech developing therapies for neuropsychiatric diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
LB Pharmaceuticals IPO Registration Document (S-1)
LB Pharmaceuticals has filed to go public with an IPO on the NASDAQ.